Reported about 22 hours ago
Eli Lilly is set to acquire Verve Therapeutics, a gene-editing biotech, for up to $1.3 billion to enhance its portfolio in cardiovascular therapies. The deal reflects Lilly's strategy to expand beyond its dominant weight-loss and diabetes medications, with plans to develop a one-time gene-editing treatment to lower cholesterol in heart disease patients. The agreement includes an upfront payment and additional funds contingent on clinical milestones, as both firms push forward in an evolving market.
Source: YAHOO